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Abstract Approximately 25 % of clinically important
drugs and numerous environmental carcinogens are metab-
olised by CYP2D6. Variation in the CYP2D6 gene and
concomitant use of tamoxifen (TAM) with certain antide-
pressants may increase recurrence risk in breast cancer
patients due to reduced enzyme activity. In this study we
determined the appropriateness of adding CYP2D6 geno-
typing to the breast cancer genetic testing options already
available in South Africa, which include BRCA mutation
screening and transcriptional profiling to assess estrogen
receptor (ER) status. A total of 114 South African breast
cancer patients, including 52 Caucasian and 62 Coloured
(Mixed ancestry), and 63 Caucasian control individuals
were genotyped for the most common inactivating allele
(CYP2D6*4, rs3892097) previously identified in the
CYP2D6 gene. In the initial validation data set consisting
of 25 Caucasian and 62 Coloured patients, the CYP2D6*4
allele frequency was significantly higher in Caucasian com-
pared to Coloured patients (24 % vs. 3 %, p<0.001), similar
to previous findings in the general South African popula-
tion. Extended CYP2D6 genotyping was subsequently per-
formed in an implementation data set of 27 Caucasian breast
cancer patients, to determine the prevalence of depression
and use of antidepressants in a clinical setting. A medical
history of depression and/or use of antidepressants was
reported in 37 % (10/27) of these breast cancer patients
genotyped for CYP2D6*4. This translational research study
has led to increased awareness among clinicians of the
potential benefits of CYP2D6 genotyping to facilitate pre-
vention of cumulative risk in a high-risk genetic subgroup of
breast cancer patients considered for concomitant treatment of
TAM and antidepressants that may reduce enzyme function.
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Introduction
Depression is the most common psychiatric problem in
cancer patients. As the age at diagnosis of breast cancer
decreases in the general population, the risk of depression
becomes higher (Kim et al. 2010). Younger patients suffer
more from psychiatric distress, resulting in negative effects
on quality of life and survival rate. The treatment of depres-
sion as part of a comprehensive risk reduction approach is
therefore an important consideration in patients with breast
cancer. It has been reported that between 20 % and 30 % of
breast cancer patients treated with Tamoxifen (TAM) to
reduce recurrence risk, also use antidepressants for depres-
sion or hot flashes (Nelson et al. 2006; Kim et al. 2010).
TAM is the most commonly used anti-estrogen drug for
treatment of breast cancer, due to its active metabolites,
hydroxytamoxifen and endoxifen. Selective serotonin reup-
take inhibitor (SSRI) antidepressants can decrease the effec-
tiveness of TAM because these drugs compete for the
cytochrome P450 2D6 (CYP2D6) enzyme that metabolises
TAM (Jin et al. 2005; Bernard et al. 2006). Consequently,
antidepressants that act as CYP2D6 inhibitors may increase
the risk of breast cancer relapse (Goetz et al. 2007). Anti-
depressants such as paroxetine, fluoxetine, and bupropion
strongly inhibit CYP2D6 enzyme activity, whereas sertra-
line, duloxetine and diphenhydramine are considered
moderate inhibitors. Escitalopram (Lexapro, Cipralex) ven-
lafaxine (Effexor) and citalopram appear to have a very mild
or no inhibiting effect on CYP2D6 activity (Preskorn et al.
2007; Lash et al. 2008; Holzman 2009).
Reduction in CYP2D6 activity due to enzyme inhibitors or
polymorphisms in the CYP2D6 gene has been shown to reduce
endoxifen levels (Borges et al. 2006) andmay be associated with
poorer outcome in women with breast cancer who have been
treated with TAM (Jin et al. 2005; Goetz et al. 2007; Newman et
al. 2008). In addition to antidepressants and TAM, CYP2D6 also
metabolises antipsychotics, antiarrhythmic agents (propafenone,
flecainide), beta-blockers (timolol, metoprolol, alprenolol), and
opioids such as codeine and dextromethorphan. Due to CYP2D6
expression in the brain this enzyme furthermore mediates neuro-
protection through inactivation of neurotoxins and breakdown of
endogenous neural compounds such as catecholamines (Mann et
al. 2011). Poor metabolisers have two copies of a defective
CYP2D6 gene, and as a result they metabolise drugs at a much
slower rate. This may result in a greater potential for adverse
events and lower efficacy of drugs requiring CYP2D6 activation
(Bernard et al. 2006).
Strong evidence has been provided that treatment failure
due to impaired drug metabolism may increase the risk of
recurrence of many different cancer types, not only in spo-
radic cases but also in patients with familial breast cancer
(Newman et al. 2008). Various genes have been implicated
in the development of breast cancer and those most studied
include the BRCA1 and BRCA2 genes. Germline mutations
in these two highly penetrant susceptibility genes explain
the majority of familial breast cancer and additionally in-
crease the risk for developing ovarian cancer (Sluiter and
van Rensburg 2011). The lifetime risk for developing breast
cancer is 65 % to 85 % for BRCA1 and 45 % to 85 % for
BRCA2 mutation carriers (Chen and Parmigiani 2007).
Increased frequencies of specific BRCA1 and BRCA2
mutations have been described in the South African Cauca-
sian (Afrikaans-speaking) and Coloured (Mixed ancestry)
populations (Reeves et al. 2004; Agenbag 2005; van der
Merwe et al. 2012). Three founder mutations [(BRCA1
c.1374delC (1493delC), BRCA1 c.2641G>T (2760 G>T,
E881X) and BRCA2 c.7934delG (8162delG)] account for
approximately 90 % of all BRCA mutation-positive families
in the Afrikaner population of European descent (van der
Merwe and van Rensburg 2009). A relatively frequent
BRCA2 founder mutat ion c.5771_5774delTTCA
(5999del4) has also recently been identified in 3.4 % of
Coloured and 25 % of Black Xhosa breast cancer patients
studied in the Western Cape region of South Africa (van der
Merwe et al. 2012).
The vast majority of breast cancers in postmenopausal
women are estrogen-receptor (ER)-positive (Punglia et al.
2008). However, in premenopausal breast cancer patients
who are more likely to be carriers of BRCA1 or BRCA2
familial mutations, tumours display differences with regard
to hormone receptors. While BRCA1 tumours are frequently
ER and progesterone receptor negative, BRCA2 tumours
are more commonly positive for both receptors (Lomen et
al. 1998). The lack of hormone receptor positivity in most
BRCA1 tumours suggests that treatment with TAM or other
hormonal therapy may be less effective in this patient pop-
ulation. In a study performed by Newman et al. (2008), in
which TAM-treated familial breast cancer patients were
investigated for the effect of reduced CYP2D6 activity on
clinical outcome, it was shown that the poor metaboliser
status predicted worse overall survival in patients with fa-
milial breast cancer. Contrary to several other studies, the
effect on enzyme function caused by both genetic variation
in the CYP2D6 gene and concomitant use of a potent
CYP2D6 inhibitor was taken into account. Patients with
BRCA2 mutations had a significantly worse overall survival
compared to patients with BRCA1 tumours (median surviv-
al: 7 versus 28 years; P00.008; adjusted hazard ratio, 9.7).
Based on the evidence provided in this study, it is of utmost
importance to identify genetic subgroups of breast cancer
patients most likely to benefit from CYP2D6 genotyping.
Similar to BRCA mutation testing performed only in
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selected patients who fulfil the test criteria, CYP2D6 geno-
typing may only be applicable in a subgroup of breast
cancer patients (e.g. BRCA2- and ER-positive patients con-
sidering concomitant use of TAM and antidepressants).
In light of the increased frequency of particularly BRCA2
mutations in three different South African population groups
and the fact that use of certain antidepressants can signifi-
cantly reduce the function of the CYP2D6 gene, implemen-
tation of a pharmacogenetics CYP2D6 assay is an important
consideration. The aim of this study was therefore twofold:
1) to determine the frequency of the relatively common
inactivating CYP2D6*4 allele in South African breast can-
cer patients (validation data set) and 2) to determine the
prevalence of depression/use of antidepressants in breast
cancer patients referred for genetic testing (implementation
data set). Ultimately, breast cancer patients may benefit from
the implementation of pathology supported genetic testing
(PSGT) that combines relevant clinical and laboratory infor-
mation for clinical decision-making. Although evidence-
based guidelines should ideally be developed before imple-
mentation of genomic applications, Khoury et al. (2007)
acknowledged the need to fill the remaining information gaps
through ongoing data collection and health outcome studies.
PSGT involves a combined service and research approach
that seeks to evaluate “real world” health outcomes of ge-
nomic applications (Kotze and van Rensburg 2012), whereby
overlapping aspects of translation research could provide
feedback loops to allow integration of new genetic knowledge
into clinical care (Khoury et al. 2007).
Subjects and methods
This study was approved by the Ethics Research Committee
of the University of Stellenbosch and was therefore per-
formed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki.
Study participants
This investigation consisted of a validation and implemen-
tation phase. The validation data set included 87 unrelated
female breast cancer patients between the ages of 30 and
87 years, previously subjected to BRCA1 and BRCA2
mutation analysis (Agenbag 2005, MJ Kotze, unpublished
data). DNA samples of 63 unrelated Caucasian individuals
(42 women and 21 men) were available as controls for
inclusion in the analytical validation phase of the project.
The implementation data set included 27 Caucasian breast
patients recently referred for genetic testing by private prac-
ticing clinicians; data was made available for this compo-
nent of the study from an online genetic database (http://
www.gknowmix.org). Written informed consent was
obtained from all study participants. A questionnaire was
used to document clinical characteristics and additional
information was obtained from patient records.
Analytical assay validation and CYP2D6 genotyping
Conventional polymerase chain reaction (PCR) followed by
direct DNA sequencing was performed for detection of the
inactivating CYP2D6*4 allele (rs3892097, also known as
c.1934G>A or 1846G>A) (http://genetmed.fudan.edu.cn/
dbHCCvar/result.asp), in 5 internal control DNA samples
(K1-5) obtained from healthy individuals. Direct sequencing
of the PCR fragments resulted in the identification of the
wild type, heterozygous and homozygous genotypes related
to the CYP2D6*4 allele. DNA samples of 63 unrelated
Caucasian individuals (42 women and 21 men) were subse-
quently used for analytical validation of high throughput
CYP2D6 genotyping against direct DNA sequencing as
the gold standard. DNA extracted from 114 breast cancer
patients (87 from the validation set and 27 from the imple-
mentation set) were subjected to CYP2D6 genotyping using
the ABI™ TaqMan® SNP Genotyping assay on the ABI
7900HT real-time apparatus.
Only the CYP2D6*4 allele was analysed in the study
population to evaluate the appropriateness of CYP2D6 test-
ing in clinical practice, since it was shown to be the most
common inactivating single nucleotide polymorphism
(SNP) in the CYP2D6 gene. Based on the outcome of the
study, a more comprehensive pharmacogenetic assay may
be developed that will include the six inactivating alleles
(*3, *4, *5, *6, 7 and *8) found to be responsible for 95 %
of the poor metaboliser status (Arneth et al. 2009).
Statistical analysis
Allele frequencies and genotype distribution were determined
by gene counting and HardyWeinberg equilibrium was tested
using an exact test. Linear models were used to test for an
association between age of breast cancer diagnosis and pres-
ence of a family history of cancer. This analysis was done in
all patients while adjusting for previous personal medical
history of cancer, ethnic group, body mass index, alcohol
intake, smoking and CYP2D6 genotype as fixed effects. All
analyses were done using the R software environment and the
R genetics package, both of which are freely available from
http://www.r-project.org. Results corresponding to p-values
below 0.05 are described as significant.
Results
The clinical characteristics of the 87 breast cancer patients
previously screened for mutations in the BRCA1 and 2
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genes are summarised in Table 1. The majority of patients
were postmenopausal. Approximately half of these patients
in the validation data set had a family history of cancer, with
early onset (<50 years) breast cancer reported in 26 % of
patients. The age at diagnosis of breast cancer in the study
population was significantly associated with a family history
of cancer (p<0.01), independent of various possible con-
founders including ethnicity, body mass index, alcohol in-
take, smoking or CYP2D6*4 genotype (data not shown). A
family history of cancer, expected to be closely related to
BRCA mutation status, reduced the expected average age at
diagnosis/onset of breast cancer with 8 years. A similar
effect on age of breast cancer diagnosis was not observed
in relation to the presence or absence of the CYP2D6*4
allele.
The allelic distribution of CYP2D6*4 was found to be in
Hardy Weinberg Equilibrium in both the breast cancer
patients and the controls. Genotype distribution and allele
frequencies differed significantly between the Caucasian
and Coloured population groups (p<0.001). The frequency
of the CYP2D6*4 allele and the poor metaboliser status
characterised by the homozygous genotype were highest in
the Caucasian breast cancer patients. No significant differ-
ences in genotype distribution or allele frequencies were
observed between the Caucasian patient and control groups
(Table 2). The 21 male controls were excluded from this
comparative analysis performed only in female breast can-
cer patients.
As indicated in Table 3, two of the six (33 %) BRCA-
positive patients included in the study were homozygous for
the inactivating CYP2D6*4 allele. Both poor metabolisers
(Caucasian) were ER-positive; one patient tested positive
for a mutation in the BRCA1 gene and the other was
BRCA2-positive. The BRCA2 mutation-positive patient
(sample 22) provided an example of how CYP2D6 genotyp-
ing may affect clinical management. Instead of TAM, an
alternative endocrine treatment was administered after the
patient underwent a hysterectomy due to her risk profile.
Direct DNA sequencing confirmed the real-time PCR result
of CYP2D6*4 homozygosity as obtained with the TaqMan
genotyping assay using the ABI 7900HT, as well as the
Corbett Rotor-Gene RT-PCR system (data not shown).
The above-mentioned findings prompted extended
CYP2D6 mutation analysis in an implementation data set
of 27 breast cancer patients, to also assess the use of anti-
depressants in TAM-treated breast cancer patients or
patients who considered TAM treatment. Ten patients
(37 %) referred by participating clinicians reported a med-
ical history of depression, with current use of antidepres-
sants reported in four patients (15 %). None of these patients
were homozygous for CYP2D6*4, while 4 heterozygotes
were identified (Table 4).
Knowledge of the different classes of CYP2D6 inhibitors
is very important in the heterozygous patients as their ability
to effectively metabolise TAM could be affected by reduced
enzyme activity caused by both the intermediate metaboliser
status due to CYP2D6*4 heterozygosity and concomitant
use of antidepressants. For example, one CYP2D6*4 het-
erozygous breast cancer patient (sample J) was diagnosed
with depression at the age of 48 years and had been on
various medications, including Wellbutrin (bupropion)
known to strongly inhibit CYP2D6 function (Table 4). Drug
side effects with use of antidepressants and various other
medications were also reported. This ER-positive over-
weight patient with high cholesterol levels had bilateral
breast cancer with 4 recurrent events between the ages of
39 and 57 years. She tested negative for three founder
mutations in the BRCA1 and BRCA2 genes.
Discussion
Identification of genetic subgroups of the population that are
at increased risk of cancer initiation, progression or recur-
rence due to heritable susceptibility or ineffective therapeu-
tic approaches is an important clinical consideration.
Currently, DNA-based BRCA 1 and 2 gene testing and
RNA-based transcriptional profiling including the determi-
nation of ER status are offered as a routine service to South
African patients who fulfil the criteria for these tests (Kotze
et al. 2005). This study aimed to determine the appropriate-
ness of adding CYP2D6 genotyping to the breast cancer
genetic test panel. The first step was to determine the fre-
quency of the most common inactivating CYP2D6*4 allele
Table 1 Clinical characteristics
of 87 Coloured and Caucasian
female breast cancer patients in-
cluded in the validation data set
Parameter Coloured patients
(n062)
Caucasian patients
(n025)
Total group
(n087)
Mean age (yrs) 54 57 55
Family cancer history (yes) 27 (44 %) 18 (72 %) 45 (52 %)
BRCA mutation positive 2 (3 %) 3 (12 %) 5 (6 %)
Premenopausal 17 (27 %) 6 (24 %) 23 (26 %)
Postmenopausal 45 (73 %) 19 (76 %) 64 (74 %)
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in South African breast cancer patients (validation data set).
The clinical usefulness of providing information related to
CYP2D6 genotype to participating clinicians was further-
more assessed in a pilot study focused on the prevalence of
depression and use of antidepressants in breast cancer
patients subjected to diagnostic genetic testing (implemen-
tation data set). Since reduced CYP2D6 activity can be
caused by variation in the CYP2D6 gene and/or the use of
certain antidepressants, both aspects were considered in this
study.
Breast cancer is most prevalent amongst South African
Caucasian and Asian women and is the second most com-
mon cancer among Black and Coloured women (Vorobiof et
al. 2001). This observation raises the question of whether
genetic risk factors may explain ethnic differences in breast
cancer risk. In this study, a significantly higher frequency of
the CYP2D6*4 allele was detected in Caucasian (24 %)
compared with Coloured breast cancer patients (3 %). This
finding is however unlikely to account for the higher prev-
alence of breast cancer in the Caucasian compared to Col-
oured group, since CYP2D6*4 affects drug response and
has not been associated with an increased risk of primary
breast cancer (Goetz et al. 2007). This is in accordance with
the failure to detect a difference in allele frequencies for
CYP2D6*4 between the Caucasian patient and control
groups. Since CYP2D6*5 is relatively common in the Col-
oured population (Gaedigk and Coetsee 2008), future mu-
tation analysis should be extended to include this assay.
More than 75 CYP2D6 allelic variants have been identified
to date (Bernard et al. 2006) and six inactivating alleles (*3,
*4, *5, *6, *7 and *8) are responsible for approximately
95 % of the poor metaboliser status in most populations
(Arneth et al. 2009).
The current debate in the literature as to whether
CYP2D6 pharmacogenetic testing of breast cancer patients
has clinical relevance highlights the importance of defining
the selection criteria for a subgroup of patients where the
potential benefits would outweigh the risk of unnecessary
genetic testing. No statistically significant associations were
observed between CYP2D6 genotype and recurrence risk in
TAM-treated patients in recent clinical trials (Rae et al.
2012; Regan et al. 2012). In contrast, strong evidence pro-
vided by numerous previous studies showed that CYP2D6
genotype is directly (Newman et al. 2008) as well as indi-
rectly (Jin et al. 2005) associated with the survival of breast
cancer patients treated with TAM (Kiyotani et al. 2010). In a
study by Schroth et al. (2009) performed in 1,325 patients,
recurrence rates were 14.9 % for extensive (wild-type geno-
type), 20.9 % for intermediate (heterozygotes) and 29 % for
poor metabolisers (homozygotes) at 9 years of follow-up.
All-cause mortality rates were 16.7 %, 18.0 % and 22.8 %,
respectively. Conflicting results reported in the literature
may be attributed to differences related to TAM combina-
tion therapy, genotyping comprehensiveness, and CYP2D6
inhibitor coadministration (Hertz et al. 2012). These include
frequent use of antidepressants prescribed to treat depres-
sion in breast cancer patients and/or menopausal vasomotor
symptoms such as hot flashes. TAM treatment may induce
or aggravate depression or anxiety, and commonly causes
hot flashes (Kim et al. 2010). During the research-focused
Table 3 Breast cancer patients
with BRCA mutations in relation
to CYP2D6 genotype
NA not available
Sample Age Ethnic group ER status BRCA mutation positive CYP2D6*4
77 41 Caucasian Negative BRCA1 Wild-type
140 52 Caucasian Positive BRCA1 Homozygous
22 48 Caucasian Positive BRCA2 Homozygous
23 45 Coloured NA BRCA2 Wild-type
38 63 Caucasian NA BRCA2 Wild-type
66 63 Coloured NA BRCA2 Wild-type
Table 2 Comparison of geno-
type distribution and allele fre-
quencies for CYP2D6*4
between the Caucasian and
Coloured study groups
Caucasian Control
group
(n042)
Caucasian
patient group
(n025)
Coloured
patient group
(n062)
Caucasian patients
to controls
Caucasian to Coloured
patients
Allele
G 70 (83 %) 38 (76 %) 120 (97 %) P00.335 P<0.0001
A 14 (17 %) 12 (24 %) 4 (3 %)
Genotype
GG 29 (69 %) 16 (64 %) 59 (95 %) P00.282 P00.0001
GA 12 (29 %) 6 (24 %) 2 (3 %)
AA 1 (2 %) 3 (12 %) 1 (2 %)
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implementation phase of our study, it was found that 37 %
(10/27) of breast cancer patients from the implementation
data set suffers from depression, while the use of antide-
pressants for depression were documented in four patients
(15 %). These findings are in agreement with previous
studies which reported that between 20 % and 30 % of
TAM-treated breast cancer patients also use antidepressants
(Nelson et al. 2006; Kim et al. 2010).
TAM is the standard 5 year endocrine treatment for
premenopausal and postmenopausal women with ER-
positive breast cancer. In contrast, aromatase inhibitors are
frequently prescribed for postmenopausal women (Kim et
al. 2010). The use of aromatase inhibitors has been pro-
hibited in premenopausal breast cancer patients due to the
activation of ovarian functions implicated in polycystic
ovarian diseases. In premenopausal patients for whom the
use of aromatase inhibitors is inappropriate, TAM is the
treatment of choice. Given the link between CYP2D6 geno-
type status and clinical outcome in risk allele carriers on
TAM, it is likely that aromatase inhibitors would be the
preferred treatment for postmenopausal women with defi-
ciencies in TAM metabolism (Kim et al. 2010; Punglia et al.
2008). Newman et al. (2008) suggested that for postmeno-
pausal patients with BRCA2 mutations and the CYP2D6
poor metaboliser genotype, an aromatase inhibitor would be
the drug of choice.
The above-mentioned recommendation was of particular
relevance in at least one patient with a founder BRCA2
mutation found to be homozygous for the CYP2D6*4 allele
(sample 22). This ER-positive breast cancer patient reported
a strong family history of breast cancer, which was shown in
this study to be associated with an 8 year (on average)
earlier onset of breast cancer irrespective of whether a
mutation has been identified in the BRCA1 or BRCA2
genes. Based on this patient’s CYP2D6*4 genotype and
the fact that she had a hysterectomy, the treating oncologist
prescribed an aromatase inhibitor instead of TAM treatment.
The proven clinical utility of CYP2D6 genotyping resulting
in a change in clinical management in this patient, has led to
increased awareness of the potential consequences of
CYP2D6 inactivation. This has also translated into avoid-
ance of concomitant use of TAM and inactivating antide-
pressants in an increasing number of breast cancer patients.
The CYP2D6*4 heterozygote who had at least four episodes
of recurrent breast cancer between the ages of 39 and
57 years (sample J) provides an example of where this
information could have been relevant if provided when she
first presented with bilateral breast cancer. She has been
diagnosed with depression at the age of 48 years and has
subsequently been treated with three different antidepres-
sants, of which the use of Wellbutrin (bupropion) reported at
entry into this study is known to strongly inhibit CYP2D6
activity. This ER-positive breast cancer patient reported side
effects with use of antidepressants and various other medi-
cations. Arimidex (anastrozole), an aromatase inhibitor, was
subsequently prescribed due to her current postmenopausal
status. This case provides insight of how a patient’s quality
of life and well-being could be adversely affected by re-
duced CYP2D6 activity compromised further by use of
antidepressants metabolised by CYP2D6. Extended muta-
tion analysis of the CYP2D6 gene as well as the entire
BRCA1 and 2 genes are considered in this patient to further
investigate the cause of her poor treatment outcome.
The above-mentioned information explains what is meant
by Khoury et al. (2007), who stated that evaluation of the
interaction between providers and patients would enable the
assessment of risks and benefits outside the context of ran-
domized clinical trials. These authors acknowledged that
while the translation research pathway for therapeutics is
relatively straightforward, it is less clear for genetic tests that
may provide useful information only in a subgroup of patients
in some populations. Lorizio et al. (2011) found that CYP2D6
genotyping in breast cancer patients affects choice of therapy
even in the absence of definitive data on clinical impact. This
confirms the value of genetic information to guide treatment
decisions on an individual basis, compared to a one-size-fits-
all approach applied in most clinical trials. CYP2D6 genotyp-
ing is particularly relevant in the local population due to the
increased frequency of BRCA2 founder mutations (van der
Merwe et al. 2012) and the high recurrence risk associated
with reduced CYP2D6 activity in mutation-positive patients
(Newman et al. 2008). Since CYP2D6*4 is virtually absent in
the Black South African population (Wright et al. 2010),
genotyping for this allele would not be appropriate in this
particular ethnic group.
We believe that the same path used for development and
implementation of genetic tests for high-penetrance genetic
variations identified in the BRCA1 and 2 genes should be
followed for low-penetrance genetic variations such as those
in the CYP2D6 gene, with the exception that known
Table 4 Breast cancer patients with a medical history of depression
analysed during the implementation phase of the study
Sample Age CYP2D6*4 Antidepressant
A 48 Wild-type Not provided
B 58 Wild-type Wellbutrin
C 47 Wild-type Not provided
D 54 Wild-type Zoloft, Wellbutrin
E 45 Wild-type Cipralex
F 60 Heterozygous Not provided
G 46 Wild-type Not provided
H 59 Heterozygous Not provided
I 68 Heterozygous Not provided
J 57 Heterozygous Cipramil, Cipralex, Wellbutrin
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environmental exposures must also be taken into account.
Integration of CYP2D6 genotype information into the clinical
decision-making process would require careful consideration
of all possible determinants of CYP2D6 metabolic activity.
Although all determinants of CYP2D6 metabolic activity
have not yet been identified and some are poorly understood,
current knowledge related to the consequences of concomitant
use of TAM and CYP2D6 inhibitors is well-documented and
needs to be communicated to clinicians and their patients. The
phenotypic expression of genetic variation in the CYP2D6
gene is modulated by various external factors including phys-
iological states (e.g. pregnancy) and certain herbal products.
Borges et al. (2010) used genotype, concomitant medication
and phenotype data to develop a CYP2D6 activity score that
incorporates both CYP2D6 genotype and CYP2D6-mediated
drug interactions. Correlation of this score with CYP2D6
phenotype represented a significant improvement over the
use of CYP2D6 genotype alone.
Multiple gene/mutation testing in the context of the
patient’s medical and/or family history provides a basis for
development and formulation of personalised cancer prog-
nostication, drug treatment and lifestyle-related risk reduc-
tion programs (Cleator and Ashworth 2004). CYP2D6
genotyping has recently been included as the pharmacoge-
netics component of a multi-gene test for cardiovascular
disease (CVD) (Kotze et al. 2003; Kotze and van Rensburg
2012), due to increased risk of muscle pain in patients taking
cholesterol-lowering medication metabolised by CYP2D6
(Frudakis et al. 2007). Due to the potential significance of
CYP2D6 genotyping in breast cancer patients and the in-
creased risk of thrombophilia and cardiac complications
with the use of chemotherapy and hormonal treatment (e.g.
TAM, HRT), the development and validation of a compre-
hensive screening strategy is hereby warranted to improve
well-being and quality of life. In this study the PSGT ap-
proach—initially developed for risk management of CVD
and related medical conditions (Kotze and van Rensburg
2012)—was applied during the implementation phase of this
study to assess the clinical usefulness of combining diag-
nostic and pharmacogenetic testing in breast cancer patients.
Assessment of CVD risk factors in breast cancer patients is
supported by the direct link between an increased risk of
postmenopausal breast cancer and the metabolic syndrome
characterised by central obesity, insulin resistance, hyper-
tension and/or hyperlipidemia (high triglycerides and/or low
HDL-cholesterol levels) (Rosato et al. 2011). These findings
support the implementation of CYP2D6 genotyping as part
of a multi-gene test that takes co-morbidities such as obesity
(King et al. 2003; Li et al. 2009), family history, ethnicity,
ER status, BRCA mutation status and use of antidepressants
into account prior to TAM treatment of breast cancer
patients. Although CYP2D6*4 is not deterministic by itself
to cause disease, it may become clinically relevant in the
presence of environmental co-factors or co-inheritance with
other genetic risk factors (Mellick 2006; Newman et al.
2008).
This study contributed to an increased awareness of the
important role clinicians can play in identifying breast cancer
patients who may benefit from CYP2D6 genotyping, based
on their unique genetic background and concomitant use of
TAM and certain antidepressants. While it remains uncertain
whether a pharmacogenetic profile should be obtained prior
to initiating TAM treatment, we conclude that genetic testing
performed as part of a comprehensive risk reduction strategy
would provide useful support for clinical decision-making in
selected patients. Two of the six (33 %) BRCA-positive
patients included in the validation data set were homozygous
for the inactivating CYP2D6*4 allele. Prospective studies are
therefore warranted to determine the effect of CYP2D6 status
on health outcomes in BRCA-positive South African breast
cancer patients treated with TAM.
CYP2D6 genotyping has relevance in several clinical
domains and represents one of several pieces of information
that clinicians may consider in guiding the choice of therapy
for each patient. This includes an important role in cardio-
vascular pharmacogenomics that may be relevant in some
breast cancer patients. The weight of current scientific evi-
dence in relation to risk-benefit assessment supports
CYP2D6 genotyping in breast cancer patients who (1) are
receiving TAM and (2) are at high risk for tumour recur-
rence (e.g. family history, BRCA1/2 mutation-positive) or
(3) are required to take potential competing antidepressants.
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